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Purpose: Medication nonadherence is common in the treatment of patients with severe mental 
illness and is a frequent cause of relapse. Different formulations have been developed in an 
effort to improve medication adherence. The aim of this study was to explore whether there are 
differential clinical outcomes between two different formulations of olanzapine (orodispersible 
tablets [ODTs] vs standard oral tablets [SOT]) for the treatment of nonadherent patients with 
schizophrenia or bipolar disorder.
Methods: Data for this analysis were from an observational study conducted in Europe (N=903). 
Adult schizophrenia and bipolar disorder patients in outpatient settings who initiated or changed 
to either olanzapine ODT or SOT according to physician decision within the last 45 days were 
eligible for enrollment. The follow-up period was 1 year. Of the 903 participants, 266 nonadher-
ent patients (Medication Adherence Rating Scale score 0–4 at baseline) were included in the 
analysis. Clinical outcomes of interest were: 1) hospitalization and 2) relapse identified by the 
participating psychiatrist or hospitalization. An adjusted logistic regression model was fitted.
Results: Patients taking ODT had more severe illness at baseline (P,0.001) as assessed with 
the Clinical Global Impression with mean (standard deviation [SD]) scores of ODT 4.63 (1.03) 
and SOT 4 (1.16). In the regression models adjusted for potential confounders, patients taking 
ODT had significantly lower odds for hospitalization (odds ratio  =0.355; 95% confidence 
interval =0.13–0.974) and relapse or hospitalization (odds ratio =0.368; 95% confidence inter-
val =0.183–0.739), respectively.
Conclusion: Nonadherent patients with schizophrenia or bipolar disorder treated with the 
orodispersible formulation were less likely to be hospitalized or suffer relapse compared to 
those patients taking the standard oral coated tablets.
Keywords: olanzapine, schizophrenia, bipolar disorder, orodispersible formulation, relapse, 
hospitalization
Introduction
A substantial proportion of patients with severe mental illnesses such as schizophrenia 
and bipolar disorder do not fully benefit from the wide availability of effective drugs 
to treat and prevent the symptoms of these conditions due to nonadherence. Although 
the adherence rate varies widely between studies, it is generally known to be about 
40%–60% in patients with schizophrenia,1 while ~40% and 75% of patients have been 
reported to stop taking medication within 1 and 2 years, respectively.2 Furthermore, 
a high rate of suboptimal adherence has also been reported in patients with bipolar 
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disorder (69%).3 In a recent systematic review, positive 
attitudes to medication and illness insight were the only fac-
tors consistently associated with better adherence in patients 
with schizophrenia, while mixed results were found for other 
factors such as symptom severity and side effects.1
Nonadherence in severe mental illness may exacerbate 
symptoms and lead to relapse and hospitalization.3,4 For 
instance, in patients with a first episode of psychosis, non-
adherence was identified as the strongest single predictor 
of relapse,5 while a recent study from China showed that 
nonadherent patients were 2.5 times more likely to relapse 
in the year following discharge than adherent patients.6 
Furthermore, compared to patients with no gaps in medica-
tion therapy, those patients with gaps of .30 days over a 
1-year period had a nearly fourfold risk of being hospitalized, 
with even a gap of 1–10 days doubling the risk.7
Given that nonadherence is a potentially preventable cause 
of adverse clinical outcomes including relapse and hospital-
ization, different types of formulations have been developed 
in an attempt to improve adherence. These delivery systems 
include long-acting injections, liquid formulations, oral gran-
ules, transdermal patches, and orodispersible tablets (ODTs).8 
For example, olanzapine is a well-established drug used to 
treat patients with schizophrenia and bipolar disorder. Oral 
olanzapine is available in the form of ODTs and standard oral 
tablets (SOT). The ODT formulation of olanzapine is designed 
to dissolve upon contact with saliva and cannot be easily spat 
out,8 and may be preferable for patients who are reluctant or 
unable to swallow tablets.9 Previous studies have shown that 
the ODT formulation is associated with higher adherence 
rates,8,9 increased patient preference,10,11 and improved ease 
of administration, which may reduce the burden of treatment 
not only on patients but also on caregivers.12
Despite the potential benefits associated with ODT,13 
particularly in terms of adherence, there are no studies to date 
which have compared the effects of different oral forms of 
olanzapine on the hospitalization and relapse rates in patients 
with severe mental disorders, while studies on the use and 
effectiveness of different oral formulations of olanzapine 
in natural settings (eg, routine care in outpatient settings) 
are scarce. Furthermore, data on nonadherent patients are 
limited as they are rarely included in clinical trials.14 Thus, 
the aim of this study was to assess whether nonadherent 
patients with schizophrenia or bipolar disorder have differ-
ent hospitalization and relapse rates when treated with ODT 
compared to SOT within a follow-up period of 12 months in 




Details regarding the study design have been published 
previously.15–17 Briefly, data for this post hoc analysis were 
obtained from a prospective, observational (noninterven-
tional), naturalistic, multicenter, multicountry study (France, 
Germany, and Greece) designed to compare medication 
adherence between two oral forms of olanzapine (ODT vs 
SOT) in patients with schizophrenia or bipolar disorder. 
Patients were followed up for 1 year, with up to five study 
visits at ~3-month (±1 month) intervals. Data collection 
occurred when the patients attended their regular clinic visits. 
The participating psychiatrists or their designees conducted 
the assessments. All investigators attended a start-up meeting 
which consisted of training in the study procedures and ques-
tionnaire administration. Each participating psychiatrist was 
asked to enroll, consecutively, up to eight eligible patients, 
in order to limit selection bias.
Patients
Patients were eligible for enrollment if they met both of the 
following inclusion criteria: 1) adult patients diagnosed with 
schizophrenia or any type of bipolar disorder based on the 
Diagnosis and Statistical Manual of Mental Disorders, Fourth 
Edition, and 2) patients for whom their physician decided to 
begin antipsychotic treatment with olanzapine (either ODT 
or SOT), according to the approved marketing authorization, 
within the last 45 days (either as treatment initiation or as 
switch from another antipsychotic). The exclusion criteria 
were the following: 1) currently receiving treatment with 
investigational drugs or procedures at enrollment (or during 
the study period) and 2) any contraindication for olanzapine 
(eg, hypersensitivity, risk for narrow angle glaucoma).
A total of 903 patients with schizophrenia or any type 
of bipolar disorder from outpatient or hospital settings were 
enrolled in this study between April 2007 and April 2008. 
The last study visit occurred in May 2009. Patients with 
schizoaffective disorder were not included in the analysis, as 
olanzapine is not approved specifically for its treatment in the 
countries included in the study. The protocol did not restrict 
use to antipsychotic monotherapy or combination therapy, 
in order to obtain an unbiased sample. This was also done 
to reflect medication decisions in real-world settings where 
combination therapy is not uncommon. All treatment deci-
sions were made at the discretion of the treating physician 
and patient, including the choice of olanzapine formulation. 
Of the 903 patients, 266 nonadherent patients, defined as 
having a baseline rating of 0–4 in the Medication Adherence 




Orodispersible olanzapine and relapse
Rating Scale (MARS), constituted the final analytical sample 
(details of this scale can be found below). Although the 
MARS does not have an established cut-off, in line with a 
previous study using the same dataset,16 we used 4 as the cut-
off for MARS. This corresponded to the lowest tertile of the 
MARS score distribution, and we judged that scores in this 
range are highly likely to have clinical implications.
ethical approval
The study was approved by ethical review boards as required 
by local law and was conducted in accordance with the 
ethical principles that have their origin in the Declaration 
of Helsinki. The specific ethics committees that approved 
the study are: 1) Comité consultatif sur le traitement 
de l’information en matière de recherche dans le domaine 
de la santé (France), 2) Landesärztekammer Hessen Ethik-
Kommission (Germany), and 3) Papageorgiou Regional 
General Hospital of Thessaloniki (Greece). All patients 
provided written informed consent.
Outcome
Two clinical outcomes during the follow-up period 
(12 months) were assessed in this analysis: 1) inpatient hospi-
talization for any reason and 2) relapse. Relapse was defined 
as either an inpatient hospitalization or a relapse identified 
by the participating psychiatrist. Information on these events 
was recorded during follow-up at each visit.
Other variables
Clinical severity was measured with the Clinical Global 
Impression (CGI) scale for Bipolar Disorder (CGI-BP)18 
or Schizophrenia (CGI-SCH).19 However, for this study, 
we only used the general severity score, which is included 
in both scales and is equivalent to the original CGI score, 
for the sake of consistency. Medication adherence was 
measured with the MARS, which is a ten-item self-reported 
measure ranging from 0 to 10, with higher scores represent-
ing better adherence. The MARS has demonstrated a high 
level of validity compared to existing self-report measures, 
and assesses a range of behaviors and attitudes linked to 
adherence.20 Information on physical comorbidities such as 
diabetes, hypertension, hyperlipidemia, and obesity was also 
obtained. Those who had at least one physical comorbidity 
were considered to have any physical condition.
statistical analysis
Baseline patient characteristics and by treatment and by 
relapse were described and compared using the chi-squared 
test (or Fischer’s exact test) and Mann–Whitney U tests for 
categorical and continuous variables, respectively. To study 
the effect of the baseline treatment form on the post-baseline 
hospitalization as well as the relapse rates, multivariable 
logistic regression models were employed. The models were 
adjusted for relevant baseline covariates (CGI, diagnosis, 
sex, country, age, any physical condition, and time since 
first episode). CGI, age, and time since first episode were 
included in the models as continuous variables, whereas other 
variables were included as categorical variables. Odds ratios 
(ORs) and 95% confidence intervals (CIs) are presented. 
A P-value ,0.05 was considered to be statistically signifi-
cant. Data analysis was carried out with SAS® software (SAS 
Institute, Cary, NC, USA), version 9.3.
Results
A total of 266 nonadherent patients (116 females and 
150 males) at baseline were included in the analysis, of 
whom 195 and 71 had schizophrenia and bipolar disorder, 
respectively. The mean age (standard deviation [SD]) was 
38.7 (12.6) years. SOT and ODT were administered to 89 
and 177 patients, respectively. Of these 266 individuals, at 
the final visit, only 33.7% continued to be nonadherent, and 
there were 8 individuals who had to discontinue the study 
for incomplete compliance (n=3; SOT 2 vs ODT 1), patient 
request (n=4; SOT 3 vs ODT 1), and intolerability (n=1; 
ODT 1). The mean (SD) MARS scores at the final visit 
were not significantly different between the two treatment 
groups (SOT 5.5 [2.6] and ODT 5.9 [2.5]; Student’s t-test 
P=0.2994).
There was a significant difference in terms of the propor-
tion of those taking different forms of tablets by country; 
ODTs were used more than twice as frequently in Greece 
as in France (Table 1). Furthermore, the mean CGI was 
significantly higher (ie, higher disease severity) among 
those taking ODT compared to those taking SOT (4.63 vs 4; 
P,0.001). There were no significant differences in terms 
of sex, diagnosis, any physical condition, age, years since 
first treatment, and MARS score between the two treatment 
groups. The relapse rates by the baseline characteristics are 
provided in Table 2. Patients who experienced relapse during 
the follow-up period were significantly more likely to have 
at least one physical health condition, longer time since first 
treatment, and higher CGI scores at baseline.
The overall hospitalization and relapse rates were 9.8% 
and 28.6%, respectively. In the unadjusted analysis, the hos-
pitalization rate was significantly higher in the SOT group 
compared to the ODT group (16.9% vs 6.2%; P=0.0058). 














Female 43.6% 35.3% 64.7%
Male 56.4% 32% 68%
country ,0.0001
France 28.2% 62.7% 37.3%
germany 22.9% 39.3% 60.7%
greece 48.9% 13.8% 86.2%
Diagnosis 0.9428
schizophrenia 73.3% 33.3% 66.7%
Bipolar disorder 26.7% 33.8% 66.2%
Any physical condition(s)d 0.7432
no 74.8% 32.7% 67.3%
Yes 25.2% 34.9% 65.1%
Age (years); mean (sD) 38.7 (12.6) 40.2 (13.5) 38 (12) 0.2188
Years since first treatment; mean (SD)e 12.1 (9.7) 13.5 (10.7) 11.4 (9.1) 0.1209
MArs at study entryf; mean (sD) 2.5 (1.37) 2.45 (1.31) 2.53 (1.40) 0.5494
cgi; mean (sD) 4.42 (1.11) 4 (1.16) 4.63 (1.03) ,0.0001
Polypharmacy (in conjunction with olanzapine)
no 83.5% 33.8% 66.2% 0.8007
Yes 16.5% 31.8% 68.2%
Antipsychotics taken prior to study entry
Amisulpride 8.3% 18.2% 81.8% 0.1128
Aripiprazole 3.8% 40% 60% 0.7359g
chlorpromazine 7.1% 31.6% 68.4% 0.8570
clozapine 2.6% 57.1% 42.9% 0.2278g
Fluphenazine 3.4% 11.1% 88.9% 0.2797g
haloperidol 29.7% 24.1% 75.9% 0.0345
Perphenazine 3.4% 44.4% 55.6% 0.4881g
Quetiapine 4.9% 23.1% 76.9% 0.5532g
risperidone 22.6% 28.3% 71.7% 0.3390
Ziprasidone 4.9% 7.7% 92.3% 0.0664g
Zuclopenthixol 2.6% 57.1% 42.9% 0.2278g
Other antipsychotic 4.5% 33.3% 66.7% 1.000g
Notes: acolumn percentage. brow percentage. cThe difference between the sOT and ODT groups was tested with chi-squared tests and Mann–Whitney U tests for 
categorical and continuous variables, respectively. dn=262 (overall), n=87 (sOT), n=175 (ODT). en=258 (overall), n=87 (sOT), n=171 (ODT). fThe MArs ranges from 0 to 10, 
with higher scores being associated with better compliance. gFischer’s exact test.
Abbreviations: cgi, clinical global impression; MArs, Medication Adherence rating scale; ODT, orodispersible tablet; sD, standard deviation; sOT, standard oral 
tablets.
Although the relapse rate was also higher among patients 
on SOT compared to ODT (36% vs 24.9%), the difference 
was of borderline statistical significance (P=0.059; Figure 1). 
The effect of treatment form on hospitalization (Table 3) and 
relapse (Table 4) estimated by multivariate logistic regression 
revealed that patients taking ODT had significantly (64.5% 
and 63.2%, respectively) lower odds for hospitalization 
(OR =0.355; 95% CI =0.13–0.974) and relapse (OR =0.368; 
95% CI =0.183–0.739), respectively.
Our study protocol included individuals who were on 
polypharmacy (ie, taking another antipsychotic in conjunc-
tion with olanzapine). In order to assess whether this affected 
our results, we conducted a sensitivity analysis by excluding 
those who were on polypharmacy from the analysis. The sen-
sitivity analysis showed that there were no appreciable 
changes in the results, meaning that polypharmacy was 
unlikely to have affected our results.
Discussion
This post hoc analysis examined the clinical outcomes of non-
adherent schizophrenia and bipolar disorder patients treated 
with either SOT or ODT at baseline over a 1-year period. 
The study found that patients on ODT had 64.5%–63.2% 
lower odds for hospitalization and/or relapse compared to 
those on SOT, despite the fact that disease severity was more 
pronounced in the ODT group at baseline. Our study results 
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point to a possible clinical benefit of ODT in nonadherent 
patients – a group for which only limited data exist due to 
their tendency to not participate in clinical trials.
Our finding that those on ODT had more severe disease 
at baseline is in line with a previous study9 and may reflect 
attitudes of psychiatrists who tend to prescribe ODT to 
patients who are more likely to be noncompliant, severely ill, 
or aggressive. The lower hospitalization/relapse rate among 
patients on ODT, despite more severe illness at baseline, 
may be attributable to improvements in adherence, given that 
nonadherence has been reported to be the single strongest 
predictor of relapse.5
In an observational study with a follow-up period of 
6 weeks, ODT was not only significantly associated with 
improvements in clinical symptoms, but also with improve-
ments in adherence, attitude, and nursing care burden in 
acutely ill nonadherent patients with schizophrenia.8 In par-
ticular, improvements in adherence were observed at as early 
as 1 week. Also in this study, although the sample consisted 
of noncompliant patients at baseline, the majority (75.3%) 
of patients completed the 6-week study and expressed posi-
tive opinions about taking ODT throughout the study period. 
It has been suggested that ODT tablets may increase accep-
tance of medication due to ease of intake and the difficulty 
in discarding the dose, and the evident improvements in 
psychotic symptoms accompanied by minimal side effects.





Female 70.7 29.3 0.8145
Male 72.0 28.0
country (%)




schizophrenia 73.3 26.7 0.2544
Bipolar disorder 66.2 33.8
Any physical condition (%)
no 7 25 0.0252
Yes 60.6 39.4
Age (years); mean (sD) 38 (12.4) 40.6 (12.9) 0.1035
Years since first treatment; 
mean (sD)
11.1 (9.4) 14.5 (10.1) 0.0066
MArsb; mean (sD) 2.58 (1.34) 2.30 (1.42) 0.1592
cgi; mean (sD) 4.32 (1.05) 4.66 (1.24) 0.0051
Notes: aThe difference between the relapse groups was tested with chi-squared 
tests and Mann–Whitney U tests for categorical and continuous variables, 
respectively. bThe MArs ranges from 0 to 10, with higher scores being associated 
with better compliance.
Abbreviations: cgi, clinical global impression; MArs, Medication Adherence 
rating scale; sD, standard deviation.
Figure 1 hospitalization and relapse rate by medication formulation at baseline.
Abbreviations: ODT, orodispersible tablet; sOT, standard oral tablets.
Table 3 effect of treatment form on hospitalization estimated by 
multivariable logistic regression




ODT (vs sOT) 0.355 0.13 0.974 0.0444
cgi 1.622 1.045 2.516 0.0309
schizophrenia  
(vs bipolar disorder)
1.074 0.387 2.984 0.8907
Female (vs male) 1.295 0.522 3.216 0.5773
country 0.0535
France 1 1 1
germany 0.247 0.063 0.974
greece 0.35 0.119 1.025
Age (years) 0.974 0.918 1.034 0.3867
Any physical conditions 1.203 0.423 3.42 0.7289
Time since first episode (years) 1.039 0.97 1.114 0.2762
Note: Model is adjusted for all variables in the table.
Abbreviations: cgi, clinical global impression; ODT, orodispersible tablet; 
Or, odds ratio; sOT, standard oral tablets.
Table 4 effect of treatment form on relapse estimated by 
multivariable logistic regression




ODT (vs sOT) 0.368 0.183 0.739 0.0049
cgi 1.545 1.158 2.06 0.0031
schizophrenia  
(vs bipolar disorder)
0.809 0.415 1.579 0.5347
Female (vs male) 1.068 0.58 1.969 0.8317
country
France 1 1 1 0.1396
germany 0.501 0.206 1.222
greece 1.158 0.551 2.433
Age (years) 0.99 0.956 1.026 0.5884
Any physical conditions 1.756 0.891 3.46 0.1036
Time since first episode (years) 1.034 0.99 1.081 0.1334
Note: Model is adjusted for all variables in the table.
Abbreviations: cgi, clinical global impression; ODT, orodispersible tablets; 
Or, odds ratio; sOT, standard oral tablets.





Furthermore, in another observational study of acutely ill 
patients with schizophrenia requiring emergency treatment, 
increase in the rate of medication acceptance was more pro-
nounced in the ODT group compared to the SOT group as 
follows: (baseline vs after 2 weeks) positive attitude toward 
medication (ODT 31.6% vs 68.4%; SOT 58.0% vs 78.3%), 
ingestion (ODT 48.9% vs 83.4%; SOT 75.4% vs 89.4%), and 
nursing effort (ie, no extensive nursing effort was needed to 
administer medication; ODT 53.9% vs 86.2%; SOT 81.1% 
vs 92.8%).9
In addition, it is of particular importance to consider the 
patient’s preference in terms of treatment in disorders such as 
schizophrenia and bipolar disorder, which frequently require 
long-term treatment, as this may influence longer-term adher-
ence with treatment and subsequent clinical outcomes. In a 
12-week randomized, crossover, open-label study, patients 
with stable schizophrenia who were on olanzapine SOT 
monotherapy were randomly assigned to ODT or SOT to 
assess patient preference for these different formulations. 
At the end of the study, a significantly higher proportion 
of patients claimed to prefer ODT over SOT (61% vs 27%; 
P,0.001).11
The study results should be interpreted in light of sev-
eral limitations. First, we were unable to conduct stratified 
analyses by disorder type (ie, schizophrenia or bipolar dis-
order) due to the small sample size. Second, the data were 
drawn from an observational study in which allocation of 
treatment form was not at random. While we adjusted for 
potential confounders, it is possible that there are other fac-
tors related to clinical outcome and physician’s choice of 
drug formulation that were not measured in the study. Thus, 
our results should not be considered as a direct comparison 
of the effects of the two different formulations of olanzap-
ine. Third, medication adherence is notoriously difficult to 
measure, as the simple act of measuring adherence via self-
administered questionnaires, physician assessment, or pill 
counts may influence patient behavior.21 Despite this, the 
fact that our results were based on routine care provides us 
with the unique opportunity to observe the effectiveness of 
treatments in natural settings, which may be different from 
studies conducted under experimental conditions, as in a 
clinical trial. Fourth, the selection of the patients included in 
the study was based on the MARS, which measures general 
attitudes toward medication. Although 82% of the patients 
included in the analysis were taking antipsychotics imme-
diately before study entry, the rest may have based their 
answers for the MARS on experiences with other types of 
medication. Finally, assessment was not blind. However, this 
was a post hoc analysis in which the investigators were not 
aware of the study question.
Conclusion
This analysis from a real-world study found that in nonad-
herent patients with schizophrenia or bipolar disorder, those 
patients treated with the orodispersible formulation were less 
likely to be hospitalized and/or suffer relapse compared to 
those treated with the standard oral coated tablets, in spite 
of having more severe disease at baseline. More research is 
needed to uncover the factors which may underlie our find-
ings. Specifically, features of ODT such as ease of use, patient 
preference, and better adherence may be responsible for our 
findings, and these warrant further investigation.
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